Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status - CAPolista

Sint Antonius Hospital0 个研究点开始时间: 2013年9月9日最近更新: 2014年1月27日

试验速览

暂无简介。

•1. Patients who participated in the Ovidius or Triple-P study (2004-2009).
•2. Diagnosis in these studies with pneumococcal pneumonia or pneumonia due other identified organism.
•3. Age = 18 years.
•4. Signing of informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 60

•1. Diagnosis of pneumonia without an identified causative organism.
•2. Fever at time of vaccination.
•3. Previous/known allergic reaction to any of the components of the vaccine given.
•4. Mentally incompetent.
•5. Previous pneumococcal vaccination*
•* with exception of patients displaying a persistent defect in the serotype specific immune response after vaccination with the polysaccharide-based vaccine Pneumovax 23. Possibly this specific serotype defect will be ‘’repaired’’ after vaccination with the (more potent) conjugate vaccine Prevnar 13.

发起方

Sint Antonius Hospital